Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach MarketBeat - Thu Jun 4, 7:04AM CDT

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to...

ARDX : 5.27 (+2.13%)
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 GlobeNewswire - Tue May 19, 7:01AM CDT

WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization...

ARDX : 5.27 (+2.13%)
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings GlobeNewswire - Thu May 7, 7:01AM CDT

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that...

ARDX : 5.27 (+2.13%)
Ardelyx: Q1 Earnings Snapshot AP - Thu Apr 30, 3:38PM CDT

Ardelyx: Q1 Earnings Snapshot

ARDX : 5.27 (+2.13%)
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire - Thu Apr 30, 3:01PM CDT

Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million...

ARDX : 5.27 (+2.13%)
Ardelyx Earnings May Confirm Whether IBSRELA's Growth Trajectory Is Real or Rhetorical Barchart - Wed Apr 29, 4:04PM CDT

Barchart Research What to Expect from ARDX Earnings ARDX Generated April 29, 2026 Current Price $6.01 EPS Estimate $$-0.13 Consensus Rating Strong Buy Average Move 18.26% Ardelyx Earnings May Confirm Whether...

ARDX : 5.27 (+2.13%)
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings GlobeNewswire - Mon Apr 27, 7:01AM CDT

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 5.27 (+2.13%)
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 GlobeNewswire - Thu Apr 23, 7:01AM CDT

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 5.27 (+2.13%)
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer GlobeNewswire - Mon Apr 20, 7:00AM CDT

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 5.27 (+2.13%)
BMY : 58.13 (+4.16%)
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 GlobeNewswire - Thu Apr 16, 7:01AM CDT

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization...

ARDX : 5.27 (+2.13%)

Barchart Exclusives

FedEx Is Abandoning Its Supply Chain Business. FDX Stock Investors Need the Logistics Giant to Protect Its Core Network. Barchart - Sat Jul 4, 12:30PM CDT
FedEx is selling FedEx Supply Chain to shipping giant CMA CGM for $1.4 billion, narrowing its focus to premium B2B shipping, logistics, and freight moves. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.